Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990867 · ClinicalTrials.gov registry record · Phase 2
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
A Phase 2 study of Acute Ischemic Stroke, sponsored by Corxel Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 740
- Enrollment target
- 20
- Study locations
NCT06990867: Recruiting Phase 2 study of Acute Ischemic Stroke, sponsored by Corxel Pharmaceuticals.
NCT06990867 is a Phase 2 study of Acute Ischemic Stroke that is actively recruiting participants, run by Corxel Pharmaceuticals. The registered enrollment target is 740 participants, above the 322-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06990867, a Phase 2 study of Acute Ischemic Stroke, is actively recruiting participants, sponsored by Corxel Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 740 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JX10
Study Locations (20)
Other
- Corxel Investigational Site - Ghent
- Corxel Investigational Site - Blagoevgrad
- Corxel Investigational Site - Burgas
California
- Corxel Investigational Site - Long Beach
- Corxel Investigational Site - Sacramento
Michigan
- Corxel Investigational Site - Kalamazoo
- Corxel Investigational Site - Traverse City
New York
- Corxel Investigational Site - Great Neck
- Corxel Investigational Site - New York
Texas
- Corxel Investigational Site - Dallas
- Corxel Investigational Site - Houston
Colorado
- Corxel Investigational Site - Colorado Springs
District of Columbia
- Corxel Investigational Site - Washington D.C.
Florida
- Corxel Investigational Site - Delray Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
What NCT06990867 shows while recruiting
NCT06990867 is an interventional study that assigns participants to a tested intervention. The registered 740 participants enrollment target is mid-sized for trials with a published cap, above the 322-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (130% higher).
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06990867 names 20 study sites across 14 states, led by Other, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06990867 about?
NCT06990867 is a clinical study titled "Optimizing Reperfusion to Improve Outcomes and Neurologic Function". The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin...
What is the current status of trial NCT06990867?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 740 participants. The study started on 2025-05-15. Estimated completion is 2029-12-31.
What conditions does trial NCT06990867 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT06990867?
The interventions under investigation include: Placebo (DRUG), JX10 (DRUG).
Who is sponsoring clinical trial NCT06990867?
This trial is sponsored by Corxel Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990867 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06990867's enrollment target sits among peer trials
740 4th of 25 higher than 22 of 25 other Acute Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
RECRUITING · Phase 2
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
COMPLETED · Phase 2
-
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- NCT06172478 · 740 participants · Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI